DRUGS MADE IN AMERICA ACQUIS (DMAA) Fundamental Analysis & Valuation

NASDAQ:DMAA • KYG2847J1040

10.47 USD
0 (0%)
Last: Mar 13, 2026, 04:10 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This DMAA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Taking everything into account, DMAA scores 1 out of 10 in our fundamental rating. DMAA was compared to 0 industry peers in the Unkown industry. The financial health of DMAA is average, but there are quite some concerns on its profitability. DMAA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. DMAA Profitability Analysis

1.1 Basic Checks

  • In the past year DMAA was profitable.
DMAA Yearly Net Income VS EBIT VS OCF VS FCFDMAA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 -50K -100K -150K -200K -250K

1.2 Ratios

Industry RankSector Rank
ROA 2.29%
ROE 2.37%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DMAA Yearly ROA, ROE, ROICDMAA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 0 50 -50 100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for DMAA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMAA Yearly Profit, Operating, Gross MarginsDMAA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. DMAA Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for DMAA has been reduced compared to 1 year ago.
DMAA Yearly Shares OutstandingDMAA Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 20M 40M 60M
DMAA Yearly Total Debt VS Total AssetsDMAA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 200K 400K 600K

2.2 Solvency

  • An Altman-Z score of 28.57 indicates that DMAA is not in any danger for bankruptcy at the moment.
  • There is no outstanding debt for DMAA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 28.57
ROIC/WACCN/A
WACCN/A
DMAA Yearly LT Debt VS Equity VS FCFDMAA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 -50K -100K -150K -200K

2.3 Liquidity

  • A Current Ratio of 0.06 indicates that DMAA may have some problems paying its short term obligations.
  • DMAA has a Quick Ratio of 0.06. This is a bad value and indicates that DMAA is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
DMAA Yearly Current Assets VS Current LiabilitesDMAA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2024 200K 400K 600K

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. DMAA Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. DMAA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 52.35, which means the current valuation is very expensive for DMAA.
  • DMAA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.71.
Industry RankSector Rank
PE 52.35
Fwd PE N/A
DMAA Price Earnings VS Forward Price EarningsDMAA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMAA Per share dataDMAA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DMAA Dividend Analysis

5.1 Amount

  • DMAA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DMAA Fundamentals: All Metrics, Ratios and Statistics

DRUGS MADE IN AMERICA ACQUIS

NASDAQ:DMAA (3/13/2026, 4:10:05 PM)

10.47

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-17
Earnings (Next)03-18
Inst Owners70.25%
Inst Owner ChangeN/A
Ins Owners1.19%
Ins Owner Change0%
Market Cap350.95M
Revenue(TTM)N/A
Net Income(TTM)5.45M
AnalystsN/A
Price TargetN/A
Short Float %0.12%
Short Ratio0.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 52.35
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.52
P/tB 1.52
EV/EBITDA N/A
EPS(TTM)0.2
EY1.91%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS6.87
TBVpS6.87
PEG (NY)N/A
PEG (5Y)N/A
Graham Number5.56
Profitability
Industry RankSector Rank
ROA 2.29%
ROE 2.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z 28.57
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

DRUGS MADE IN AMERICA ACQUIS / DMAA FAQ

What is the fundamental rating for DMAA stock?

ChartMill assigns a fundamental rating of 1 / 10 to DMAA.


Can you provide the valuation status for DRUGS MADE IN AMERICA ACQUIS?

ChartMill assigns a valuation rating of 0 / 10 to DRUGS MADE IN AMERICA ACQUIS (DMAA). This can be considered as Overvalued.


How profitable is DRUGS MADE IN AMERICA ACQUIS (DMAA) stock?

DRUGS MADE IN AMERICA ACQUIS (DMAA) has a profitability rating of 0 / 10.


Can you provide the financial health for DMAA stock?

The financial health rating of DRUGS MADE IN AMERICA ACQUIS (DMAA) is 5 / 10.